PreCyte Inc

PreCyte Inc is a biotechnology startup based in the United States with a mission to envision a world free from cancer and neurodegenerative disease. The company is focused on developing non-invasive diagnostic tools, particularly blood tests, to enable early detection of diseases. The main challenge in creating these tests lies in the very low signal to noise ratio of blood biomarkers. In response to this challenge, PreCyte Inc is developing a proprietary tool called the indicator cell assay platform (iCAP).

The iCAP is designed to use standardized cells as biosensors to detect and respond to signals in patient blood, overcoming the issue of low abundance blood biomarkers. Additionally, the company utilizes machine learning tools to predict the disease state of patients based on the gene expression responses of the cells. This approach transforms the complex task of identifying and detecting low abundance blood biomarkers into the established practice of measuring cell culture responses in vitro.

PreCyte Inc's vision extends to the development of pan-cancer iCAP panels for cancer screening, with the goal of improving patient outcomes. Presently, the company is actively involved in developing iCAPs for the early detection of lung cancer and Alzheimer's disease.

Established in 2014, PreCyte Inc operates within the biotechnology and healthcare industries with a focus on pioneering innovative solutions for disease detection and diagnosis.